[1] 顾春梅,高振宇,卢金淼.抗血小板新药替卡格雷取代氯吡格雷的探讨[J].上海医药,2014,35(1):20-21.
[2] CANNON CP, HARRINGTON RA, JAMES S, et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO):a randomised doubleblind study [J]. Lancet,2010,375(9711):283-293.
[3] 倪金迪,沈国锋.抗血小板药预防脑卒中的应用进展[J].中国临床神经科学,2014,2(4):412-417.
[4] 何晓清,徐建国,吴泰志,等.替卡格雷Dimroth重排杂质的研究[J].中国药物化学杂志,2015,25(2):129-131.
[5] 黄阳,王兵,刘颖,等.替卡格雷的合成工艺改进[J].合成化学,2015,23(7):650-652.
[6] 陈莉莉,岑均达.替卡格雷合成路线图解[J].中国医药工业志,2011,42(2):146-150.
[7] 马志龙,周峰,吴夏冰.替卡格雷关键中间体的合成[J].中国医药工业杂志,2014,45(3):212-214.
[8] ZHANG H, LIU J, ZHANGL L, et al. Synthesis and biological evaluation of ticagrelor derivatives as novel antiplatelet agents [J]. Bioorg Med Chem Lett,2012,22(11):3598-3602.
[9] RANGANATHAN S; GEORGE K S. 2Aza3oxabicyclo[2.2.1]heptene hydrochloride:an exceptionally versatile synthon for carbocyclic sugars and nucleosides [J]. Tetrahedron,1997,53(9):3347-3362.
[10] SPRINGTHORPE B, BAILEY A, BARTON P , et al. From ATP to AZD6140:the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis [J]. Bioorganic and Medicinal Chemistry Letters,2007,21(17):6013-6018.
[11] 张燕梅.替卡格雷中间体4,6-二氯-5-氨基-2-丙硫基嘧啶的合成[J].化学试剂,2014,36(7):667-669.